Patient-Centered Reported Outcomes, Paris-Diderot University, Paris, France.
Health Economics Clinical Trial Unit (URC-ECO), Hotel-Dieu Hospital, AP-HP, Paris, France.
Neurogastroenterol Motil. 2022 Mar;34(3):e14202. doi: 10.1111/nmo.14202. Epub 2021 Jun 18.
Gas-related symptoms (GRS) are common in the general population (GPop) and among patients with disorders of gut-brain interactions but there is no patient-reported outcome evaluating these symptoms and their impact on daily life. We have previously developed a 43-item intestinal gas questionnaire (IGQ). The aim of the present study is to perform a psychometric validation of this instrument.
Participants (119 from the GPop and 186 irritable bowel syndrome (IBS) patients) were recruited from 3 countries (UK, Spain, France). IBS patients fulfilled ROME IV criteria with an IBS severity score between 150 and 300. Participants completed the IGQ, the functional Digestive Disorders Quality of Life (FDDQL), and the EQ-5D. A subgroup (n = 90) repeated the IGQ completion after 7 days on paper or electronically.
From the original IGQ questionnaire, 26 items were deleted because of poor performance. Confirmatory factorial analysis on the remaining 17 items (7 symptom and 10 impact items) yielded a 6-factor structure accounting for 67% of the variance for bloating (6 items), flatulence (3), belching (2), bad breath (2), stomach rumbling (2), and difficult gas evacuation (2). Global score (0-100) was worse among IBS vs GPop (40 ± 15 vs 33 ± 17; p = 0.0016). At the second visit, the intraclass correlation coefficient of IGQ scores was between 0.71 and 0.86 (n = 67) for test-retest reliability and 0.61-0.87 (n = 64) for equivalence between electronic and paper versions of IGQ.
The IGQ available in paper and electronic versions in 3 languages is a robust instrument for capturing and measuring GRS and their impact on daily life.
气体相关症状（GRS）在普通人群（GPop）和胃肠道-大脑交互障碍患者中很常见，但尚无评估这些症状及其对日常生活影响的患者报告结局。我们之前开发了一个 43 项肠道气体问卷（IGQ）。本研究的目的是对该工具进行心理测量验证。
参与者（来自 3 个国家/地区的 119 名普通人群和 186 名肠易激综合征（IBS）患者）被招募。IBS 患者符合罗马 IV 标准，IBS 严重程度评分在 150-300 之间。参与者完成了 IGQ、功能性消化障碍生活质量（FDDQL）和 EQ-5D。一个亚组（n=90）在 7 天后以纸质或电子形式重复完成 IGQ。
从原始 IGQ 问卷中删除了 26 个表现不佳的项目。对剩余的 17 个项目（7 个症状项目和 10 个影响项目）进行验证性因子分析，得出 6 个因子结构，解释了腹胀（6 个项目）、气胀（3 个项目）、呃逆（2 个项目）、口臭（2 个项目）、肠鸣（2 个项目）和排气困难（2 个项目）的 67%的变异性。与普通人群相比，IBS 患者的全球评分（0-100）更差（40±15 vs 33±17；p=0.0016）。在第二次就诊时，IGQ 评分的组内相关系数在 67 名参与者（测试-重测可靠性）的范围内为 0.71-0.86，在 64 名参与者（IGQ 电子和纸质版本等效性）的范围内为 0.61-0.87。
IGQ 有纸质和电子版本，提供 3 种语言，是一种可靠的工具，可用于捕捉和测量 GRS 及其对日常生活的影响。
